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To date, the standard approach to metastatic melanoma with classic 
chemotherapeutic agents has been unsuccessful. In the last 15 years, he 
identification of mutations in BRAF genes, such as BRAFV600E, led to the 
development of BRAF mutant target therapies with small biological 
inhibitors (i.e. Vemurafenib, PLX4032) that specifically block the 
constitutively active MAPK-mediated pathway. Although patients respond 
positively at first, after six-months therapy most patients relapse due to 
acquired resistance to inhibitors.  
The heterogeneity of this tumor makes the study of melanoma acquired 
resistance more complex, pointing out the importance of directing research 
towards personalized medicine. Moreover, cancer cells undergo a 
multifaceted rewiring of cellular metabolism to support their biosynthetic 
needs, and the implications and clinical relevance in melanoma acquired 
resistance to PLX4032 has not been elucidated. 
For these purposes, in this thesis a human mutant BRAFV600E PLX4032 
resistant subline was selected. It is important to note that this selection 
derives directly from tumor biopsies prior to therapy, and the treatment has 
been protracted for six months, in order to obtain a truthful model of 
resistance. 
In the first part of the work the acquisition of resistance, together with 
tumorigenicity, clonogenicity and invasiveness were assessed. 
It was also found that P-ERK and MITF, two known mediators of resistance 
in melanoma, are not overexpressed in the resistant melanoma cell line 
demonstrating to not mediate PLX4032 resistance. 
The second part of the work was focused on the identification of metabolic 
changes, that could be involved in the acquisition of resistance to BRAF 
inhibitors.   
This thesis highlights some potential key metabolic and phenotypic markers 
mediating resistance to targeted therapies in cutaneous malignant melanoma, 
emphasizing the importance to study metabolic changes that could be used 
as adjuvant target to overcome or bypass acquired resistance. 
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Melanoma is a malignancy that arises from the uncontrolled 
proliferation of melanocytes which are specialized pigment-
producing cells of neuroectodermal origin found in the epidermis, 
meninges, inner ear, leptomeninges and eye [1]. 
1.1.1 Normal organization of melanocytes 
Anatomically, melanocytes are located in the skin, between the 
epidermidis and the dermis layer, where their function is strictly 
controlled by keratinocytes (Figure 1). During skin exposure to 
UV, melanocytes are able to produce melanin, a brown pigment 
that protects the deeper layer of the skin from harmful UVR-
generated free radicals, causing the appearance of tanning [2], [3].  
In the epidermis under physiological conditions, melanocytes and 
keratinocytes form the “melanin unit”, aligned along the basement 
Figure 1. Schematic illustration of normal organization in the 
epidermis. The structure includes keratinocytes and melanin-
producing melanocytes. The melanosomes are transported to neighbour 
keratinocytes by the extension of melanocytes. The transferred melanin 
forms a shield against UVR.  
 






membrane zone.  Melanocyte dentrites extends into the upper 
layers of the epidermis, transporting pigment-containing 
melanosomes to keratinocytes. Undifferentiated keratinocytes of 
the basal layer are able to regulate melanocyte growth, number of 
dendrites and expression of cell surface molecules [4], [5]. This 
highly-ordered organizational pattern is the structural basis for 
intercellular regulation, and its organization is only disturbed 
during transformation into a nevus or a melanoma.  
1.1.2 Melanoma development 
 
Melanoma development is considered a multi-step process, and 
two models of melanoma progression based on clinical and 
histopathological features has been proposed. 
The Clark level stages are based on the description of the depth 
of melanoma during its growth in the skin (Figure 2). The first two 
stages represent the transition from a benign and confined nevus 
to an uncontrolled growth of normal melanocytes (Dysplastic 
nevus) with gain of structural atypia. During the radial-growth 
phase, melanoma has invaded intraepidermally, without showing 
metastatic property. The loss of expression of E-cadherin, a 
transmembrane protein involved in cell adhesion, and the gain of 
expression of N-cadherin determines the transition to the vertical-
growth phase. From this point, the disease is able to metastasize 













Figure 2. Clark model of melanoma progression. A benign nevus is 
represented by a local proliferation of melanocytes. The abnormal 
proliferation of melanocytes forms a dysplastic nevus, with changes in 
their phenotype. When cells start to migrate in the nearby epidermis, the 
melanocytes are in the Radial-Growth phase. If melanocytes start to lose 
the connection with surrounding keratinocytes and create new contact in 
the dermis, the vertical growth phase is initiated.  The motility of 
melanoma cells, that can reach different organs, is considered the 
metastatic phase. 
The Breslow Depth is a description of invasion of melanoma in 
the body, and it is used as a prognostic factor. The thickness of the 
melanoma is measured with a micrometer from the granular layer 
of the epidermis down to the deepest point of invasion. This 
description has been replaced by the American Joint Committee 
on Cancer (AJCC) staging system.  
1.2 STAGING 
 
In order to facilitate the clinical approaches and to improve the 
outcomes of cutaneous melanoma patients it is fundamental to 
base the treatment on accurate staging and patient stratification. 
Actual melanoma staging is based on the eight edition of American 
Joint Committee on Cancer (AJCC) staging system, based on the 
screening of more than 46 000 melanoma patients [6]. The system 
assigned a stage based on tumor-node-metastasis (TNM) scores, 
as well as additional prognostic factors. 






TNM classification is based on 3 parameters: 
 T, Tumor, describes the size of the primary tumor 
 N, Node, describes the presence of cancer cells in lymph 
nodes regions 
 M. Metastasis, describes whether the cancer has spread to 
a different part of the body 
In 2009, mitotic rate, expressed as the number of mitoses per 
square millimeter of primary tumor [7],was added as a criterion to 
define the stages. 
1.2.1 Stage 0 Melanoma – Melanoma in situ 
 
Melanoma in situ refers to lesions that have breached only the 
epidermidis (the outer layer of the skin), without growing in the 
deeper levels and did not show sign of spreading. It is considered 
a local melanoma. Stage 0 melanoma is highly curable, and 
patients are considered at low risk for local recurrence or for 
regional and distant metastases. Surgical excision is sufficient to 
solve the local melanoma. 
1.2.2 Stage I Melanoma 
 
It is possible to divide Stage I into 2 subgroups, influenced by 
thickness and ulceration status [8], which are strong predictors of 
prognosis in patients with clinically localized melanomas: 
 Stage IA: Tumor is < 1 mm thick with or without ulceration 
when viewed under the microscope 
 Stage IB: Tumor is ranged between 1mm and 2 mm 










1.2.3 Stage II Melanoma 
 
At this stage, melanoma is yet considered a local melanoma 
(together with stage 0 and stage I), but starts to extend beyond the 
epidermidis, penetrating the thicker dermis layer of the skin. 
Pathologic stage II tends to metastasize, but lymph node biopsy 
results negative. 
Stage II is divided into three subgroups: 
 Stage IIA: Tumor is between 1 and 2 mm thick with 
ulceration, or between 2 and 4 mm thick but without 
ulceration, 
 Stage IIB: Tumor is between 2 and 4 mm thick with 
ulcerations, or > 4 mm thick without ulceration 
 Stage IIC: Tumor is > 4 mm thick with ulcerations 
1.2.4 Stage III Melanoma 
 
Stage III is also known as “regional melanoma” due to the 
spreading to nearby lymph nodes, the most common first site of 
metastasis in melanoma patients [9]. 
This heterogeneous group is divided into four complex subgroups, 
based on the number of regional lymph nodes harboring 
metastatic disease, regional tumor burden and ulceration of the 
primary tumor. 
1.2.5 Stage IV Melanoma 
 
Stage IV melanoma also called “distant metastatic melanoma” has 
spread throughout the body such as the brain, lungs, liver, 
gastrointestinal tract or to distant point in the skin. This stage has 
the poorest prognosis, and the chance of survival 5 year post 
treatment is less than 10% [9]. Recently, AJCC melanoma staging 
system introduces three subcategories of stage IV melanoma: 






 Stage M1a: Metastasis reach distant skin, subcutaneous 
tissues and/or lymph nodes. Patients at this stage have the 
highest one-year survival rate (62%) among patients with 
stage IV disease; 
 Stage M1b: Metastasis spread to the lungs. Patients at this 
stage have an intermediate prognosis, with one-year 
survival rate of 53%; 
 Stage M1c: Metastasis can be found in any non-pulmonary 
visceral site or patients with an elevated serum LDH. 
Patients at this stage have the worst one-year survival 
among stage IV patients (33%). 
1.2.6 The “ABCDE” Rule to identify melanoma  
 
Screening for melanoma has been advocated for many years, due 
to the fact that early detection and excision have been regarded as 
the most important measure to lower mortality from neoplasm 
[10]. The ABCD rule was first introduced in 1985 from Friedman, 
Rigel and Kopf as a self-diagnosis method that helps people and 
patients to simply monitoring skin changes, in order to identify 
lesions that could be potential melanomas. The criteria of 
identification were: A for “Asymmetry”, B for “Border 
Irregularity”, C for “Color Variegation” and D for “Diameter 
generally greater than 6 mm” [11]. In 2004, the ABCD rule was 
revisited, adding a new letter that includes any type of change: E 
for “Enlargement”, ”Elevation” or “Evolving” [12]. 
1.2.7 Classification of cutaneous melanoma: the non-acral 
cutaneous melanoma 
 
Based on clinical and histological features, the primary histologic 
subtypes of melanoma include superficial spreading, lentigo 
maligna and nodular. From a genomic standpoint, non-acral 
cutaneous melanoma (NACM) is generally characterized as being 






made up of four major subclasses: BRAF, NRAS, NF1, and triple-
wild type. 
1.2.7.1 Superficial Spreading Melanoma 
 
Superficial melanoma (SSM) constitutes 70% of confirmed 
melanomas, and generally arises de novo or together with an 
existing nevus. SSM is generally located on the legs of womens and 
on the backs of men. Its onset is often linked to intermittent sun-
exposure as risk factor, as well as family history and Fitzpatrick’s 
phototype I and II, represented by people that in response to UV 
light are always burn or never tanned (phototype I) or usually 
burned but with a minimal tan (phototype II) [13], [14]. 
Histologically, this lesion is characterized by singles or cluster of 
epithelioid melanocytes, with abundant cytoplasm, nuclear 
pleomorphism and prominent nucleoli. Pigmentation areas 
changing from brown to red and sometimes are hypopigmentated. 
The edges of the lesions are clean and defined, but melanocyte 
proliferation can be seen extending over 25 mm. Frequently the 
immunitary response gives rises to spontaneous regression, that 
clinically appears like a white-grey depigmented area [13]. 
1.2.7.2 Nodular Melanoma 
 
Nodular Melanoma (NM) represents only 5% of melanoma 
subtypes and is again related to intermittent sun exposure. 
Differently from SSM, NM is not associated with an existing nevus 
[13] and presents a rapidly enlarging nodule.  NM is generally 
located on the trunk and limbs of patients ad arise at the age of 
50-60 with higher incidence in males [15]. Histologically NM 
appears generally as a brown mass of dysplastic tumour cells 
round and epithelioid in morphology with hyperchromatic nuclei. 
 






1.2.7.3 Lentigo Malignant Melanoma 
 
Lentigo maligna melanoma (LMM) represents 4 to 15% of 
cutaneous melanoma, and its onset is related to chronic sun 
exposed skin with an increased incidence in advanced age. The 
tumors usually arise from the invasive progression of benign 
lentigo maligna. LMM is usually located in the skin of scalp, face 
or neck, showing marked solar elastosis and other features of long-
term sun damage [13]. Histologically, the lesion presents an 
irregularly shaped and variable-pigmented macule which slowly 
enlarges. 
1.2.8 Acral Lentiginous Melanoma 
 
Acral Lentiginous melanoma (ALM) is one of the most common 
variant of melanoma in people with dark skin but arises at equal 
frequency in all races, mainly arising on the palms, soles and nail 
beds [16]. Patients with ALM tend to have poor prognosis, mainly 
caused by delays in diagnosis and advanced disease at 
presentation [17]. Histologically, ALM may have epithelioid 
cellular morphology and acanthosis, elongation of rete ridges and 





Although malignant melanoma accounts for only about 2% of all 
cutaneous malignancies, it is responsible for 75% of all skin cancer 
death. The melanoma incidence and death rate have progressively 
increased during the last 30 years [18], reaching a global incidence 
of 15-25 per 100,000 individuals [19], with 48, 000 deaths 
according to World Health Organization. In 2018, the World 
Cancer Research Foundation reported 300,000 new cases 






worldwide, and 12.1 new cases per 100,000 inhabitants in Italy, 
ranking 19th among the top 20 nations with highest number of 
diagnoses. The incidence is influenced by different parameters like 
ethnicity, geographical location, sex, anatomic distribution and 
age. Moreover, melanoma incidence is higher in the 40-60 year age 
group and in later life (> 80 years), and the median age at 
diagnosis is 57 years [19] Despite this, cutaneous melanoma still 
remains one of the most common cancers in young adults. 
1.4 RISK FACTORS 
 
Many factors that have been considered could affect the increased 
worldwide incidence of melanoma, and the risk to develop this 
cancer seems to be linked to genetic, phenotypic, enviromental 
factors and their combination [20]. 
1.4.1 Age  
 
Patient age has been considered a strong predictor of outcome, and 
an independent prognostic factor for survival in patients with 
cutaneous melanoma [21]. Increasing age is considered an adverse 
prognostic indicator of overall survival in patients with melanoma, 
due to  unfavourable clinicopathological features in the primary 
tumor, including thicker depth, higher mitotic rates and increased 
likelihood ulcerations [21], and epidemiological studies showed 
that clinical stage I/II patients with more than 70 years had more 
advanced primary tumors [22] and were associated with higher 
mortality compared with other age groups [8]. In a correlate study, 
it was shown how worse prognosis and higher mortality rate in 
stage III patients was directly correlated with age [23]. However, 
the causes of heterogeneity of primary melanoma and the diversity 
of outcomes of the primary melanomas in the young and elderly 
population have not been clearly defined [21]. Considering age and 






anatomic distribution, trunk melanomas occur often in the fith-to-
sixth decades of life, while head and neck melanomas occur more 
in the eigth decade of the life [24]. 
1.4.2 UV Exposure 
 
Development of melanoma is directly related to UV light exposure, 
especially UV-B levels, in all skin types [25]: UV radiation cause 
damage to DNA, playing a pivotal role in the pathogenesis of these 
tumors. Incidence of melanoma is inversely related to latitude of 
residence: highest in equatorial regions and less frequent in people 
who live distant from the equator [26] In this context, 
epidemiological studies described how sun and time of exposure 
patterns are directly related with melanoma development. When 
the skin is exposed to UV light, keratinocytes stimulates 
melanocytes to produce melanin via UV-induced DNA damage, 
which induces p53 tumor suppressor protein stabilization [3]. This 
allow the transcriptional activation of pro-opiomelanocortin, 
which is cleaved to produce melanocyte-stimulating hormone 
(MSH) that is subsequently released by keratinocytes to act on 
melanocytes. Melanocytes respond to the stimulus via 
Melanocortin 1 receptor (MC1R), that leads to an increasing 
intracellular level of cAMP, which in turn increases the 
microphtalmia transcription factor MITF, responsible for melanin 
synthesis activation [27]. Even if UV radiations could be 
considered an unavoidable risk factor, the exposure to UV can be 
strictly controlled.  During skin exposure to UV radiation, 
damaged DNA of keratinocytes stimulates melanocytes to produce 
melanin, which is packed in melanosomes and transported to 
keratinocytes, where it protects from UVR-generated free radicals, 
causing the appearance of tanning [3]. Paradoxically, melanocytes 
can also be transformed by UVR: in fact, UVR are able to induce 
genetic changes in the skin but also increase local production of 






growth factor and induce reactive oxygen species that can affect 
skin cells [28]. Oxidative stress can disrupt the homeostasis of 
melanocytes, compromising their survival or leading to malignant 
transformation [29]. Even though most melanoma still produce 
melanin, some damaged melanocytes lose this ability, resulting in 
a colorless appearance, which makes early diagnosis more 
challenging  [30]. 
1.4.3 Ethnicity and Geography 
 
The incidence of melanoma seems to be closely related to ethnicity, 
with a preponderant incidence in the Caucasian population. This 
variation is probably due to the reduced melanin photoprotection 
in fair-skinned people, together with variations in UV exposure 
from intermittent to chronic [31].  
Geographic location influence melanoma incidence in people of the 
same ethnicity [32].  Atmospheric absorption, latitude, altitude 
cloud cover and season are all variable that influence UV radiation 
in different geography locations. Lancaster found a correlation 
between increasing melanoma mortality and closeness to the 
equator, a phenomenon called “latitude gradient” [32], and from 
this paper similar trends were recorded over the world, with a 
higher incidence at higher latitudes. 
1.4.4 Sex 
 
Sex influence melanoma incidence differently, and in addition to 
it, sex incidence is influenced by age. It is reported that adolescent 
and young women are more susceptible to melanoma compared to 
men at the same age. Despite this, after the age of 40, the trend 
reverse, with a higher incidence among men, where the tumor 
increase more rapidly than any other malignancy [21], [33]. In 
general, men are most susceptible to melanoma than women, and 






the lifetime risk of developing is 1 in 28 for men and 1 in 44 for 
women [21]. The hypothesis formulated for this difference are 
formulated basing on behavioural and biological differences the 
two sexes. Among these, hormonal differences, pharmacokinetics 
of the drugs and different responses to infection/inflammation 
[34]. 




BRAF (V-raf murine sarcoma viral oncogene homolog B1) is a 
human proto-oncogene, member of the RAF (RApidly growing 
Fibrosarcoma) family of serine-threonine kinases (ARAF, BRAF 
and CRAF) with close overlapping functions that constitute part 
of the RAS/RAF/MEK/ERK mitogen activated protein kinase 
(MAPK) signal transduction cascade [35], [36].  
The study of three-dimensional structure of RAF proteins has 
played an important role in the characterization of mutations and 
in the formulation of new drugs act to inhibit its active status.  
Inactive RAF protein consists in a closed monomeric conformation 
in the cytoplasm, due to the intramolecular interaction between 
the carboxyl terminal lobe (C-lobe) and amino terminal lobe (N-
lobe) thanks to a flexible hinge (Figure 3 A) [37], [38]. There were 
identified three major active sites in BRAF: the nucleotide (ATP 
or ADP)-binding site, the magnesium-binding site (DFG [Asp–
Phe–Gly] motif), and the phospho-acceptor site (activation 
segment [AS]) of the two lobes [39]. In the inactive BRAF (Figure 
3A.), the AS is in a helical conformation (called “OUT” position), 
leading to the positioning of the αC helix. In the “OUT” position . 
AS conformation is extended, enabling the αC helix of the N-lobe 
to flex in the “IN” position, as a light switch (Figure 3B.) [40]. 






Moreover, the DFG “IN” position gives a catalytically competent 
active conformation [41]. 
BRAF mutations, firstly characterized in human malignancies in 
2002 [42], are present in 5-10% of all human malignancies [43],  
with a higher incidence in colorectal cancer (10%) [44], papillary 
thyroid cancer (45%) [45] and malignant melanoma (50%) [43], 
indicating that this pathway is a key oncogenic driver in multiple 
anatomic tissues [46]. Moreover, BRAF mutations affect other 
clinical subtypes of melanoma, representing the 10-20% of 
mucosal or acral melanoma, while are absent in uveal melanoma 
[47]. Moreover, BRAF mutations are typically directly related to 
young age and intermittent sun exposure [48]. The discovery of 
BRAF-activating mutations in melanoma signed a landmark 
Figure 3. Structural conformation of BRAF.  In normal conditions, 
the inactive monomer (A) own an “OUT” conformation on the active site 
(AS) had a helical conformation, positioning the αC helix in the “OUT” 
position. The active form of BRAF (B) is characterized by the extended 
conformation of the AS, enabling the αC helix to flex in the “IN” position. 
“Development of small molecule therapeutics and strategies for targeting 
RAF kinase in BRAF mutant colorectal cancer”, Adapted. 






event in the understanding of melanoma biology [35]. More than 
50 mutations in BRAF have now been described, but 40%-70% of 
malignant melanoma cases carry a missense mutation, with a 
substitution of valine with glutamic acid at codon 600 (denoted as 
V600E). This mutation is located in the activation loop of BRAF  
[49], and determines a phosphomimetic conformational change in 
the activation domain of BRAF that leads to a constitutively active 
MAPK – ERK signalling and a large increase in the basal kinase 
activity [50]: as a general result, V600E mutation in BRAF 
destabilize the inactive kinase conformation switching the 
equilibrium towards the active form, and cells are continuously 
stimulated to proliferate, while cell death programs are inhibited. 
Moreover, BRAFV600E does not require the dimerization of BRAF 
for its functions and could act like a monomer. This can result in 
a 500-fold over-activation of the BRAF kinase cascade [1]. Other 
driver mutations identified in BRAF are valine-to-lysine (V600K) 
and valine-to-arginine (V600R) mutations, which comprise 20% 
and 7% of BRAF mutations, respectively [47]. In a small group of 
melanoma, BRAF mutations occur in different position than 600, 
showing impaired intrinsic BRAF kinase activity [51]. It’s 
interesting to notice that about 80% of benign nevi harbor BRAF 
V600E mutations, pointing out how BRAF mutation alone is not 
sufficient to drive tumorigenesis [42].  
Relating BRAF mutations and UV exposure, mutations in BRAF 
were significantly more frequent in melanomas of patients 
without chronic sun exposure [52]. 
1.5.2 NRAS 
 
With 15-20% of cases, NRAS mutations at codons 12, 13 and 61 
constitute the second most common genetic alteration in non-uveal 
sites melanoma, and are associated with increased aggressiveness 






and poor survival [42]. BRAF and NRAS mutations are always 
mutually exclusive [47] and differently from BRAF, NRAS 
mutation is rare in benign melanocytic nevi [53]; however, NRAS 
play an important role in resistance to target therapy with BRAF 
inhibitors. 
NRAS tumors tend to arise in the later-life (> 55 years), and are 
correlated with chronic ultraviolet (UV) exposure in contrast with 
BRAF-mutated tumor that are more common in intermittently 
sun-exposed skin [54].  
The presence of NRAS mutations is also considered an adverse 
prognostic factor in melanoma, tending to be more aggressive than 
other subtypes with thicker lesions, elevated mitotic activity and 
higher spreading of metastasis to the lymph nodes; people who 
harbor this mutation has a lower median OS compared to non-
NRAS-mutant melanoma [55]. 
Moreover, and in contrast with BRAF-mutant melanoma, little 
progress has been made in developing targeted therapeutic 
strategies for NRAS-mutant melanoma; no effective small-
molecule inhibitors have been detected. 
1.5.3 Loss of NF1 
 
The neurofibromin 1 (NF1) gene located on chromosome 17, 
encodes for a protein that works as a negative regulator of RAS 
signal transduction pathway. In basal conditions, NF1 function is 
a GTPase-activating protein known to downregulate RAS activity 
by converting the active RAS-guanosine triphosphate (RAS-GTP) 
into the inactive form RAS-guanosine diphosphate (RAS-GDP) 
[56]. As a result, RAS/MAPK pathway results negatively 
regulated [57]. NF1 mutations are common in cancer (i.e. 
neurofibromas, plexiform neurofibromas, myeloid leukemia and 
Lysh nodules,, and affect approximately 12-18% of all melanoma 






[57]. Furthermore, desmoplastic melanoma, a rare form of cancer, 
shows a loss-of-function mutation in NF1 in more than 50% of 
patients [58]. The major consequence of loss of NF1 mutation is an 
increasing in RAS/MAPK pathway signaling. Moreover, NF1 
seems to play a role in driving resistance to RAF/MEK targeted 
therapies [56]. NF1 mutations occur in melanoma patients after 
chronic skin sun-exposure or in older individuals. Genome Atlas 
Network and Krauthammer et al. [59] point out that mutation in 
BRAF or in RAS may also have a loss-of-function in NF1. 
1.5.4 Triple Wild Type Melanoma 
 
Triple Wild-Type subtype melanoma is an heterogeneous 
subgroup characterized by a lack of hot-spot BRAF, N/H/K RAS or 
NF1 mutations [57], and a higher fraction of samples possess 
significant copy amplifications in the 4q12 minimal common 
region containing v-kit Hardy-Zuckerman 4 feline sarcoma viral 
oncogene homolog (KIT), platelet derived growth factor alpha 
(PDGFRA) and kinase insert domain receptor (KDR, VEGFR2), as 
well as amplifications in loci encompassing telomerase reverse 
transcriptase (TERT), cyclin dependent kinase 4 (CDK4) and 
cyclin D1 (CCND1) [60] (Figure 4). Only 30% of cases harbored a 
UV signature, compared to over 90% for the other three categories 
[57]. Triple wild type melanomas were frequently observed in 
males between the age of 60-70 [61]. 







Figure 4  Schematic representation of oncogenic mutations in 
melanomas. Among the most studied oncogenic mutations is it possible 
to find BRAF, NRAS, loss of NF1 and Triple Wild Type melanoma. All 
these mutations are involved in proliferation and survival pathways. 
1.6 THERAPEUTIC APPROACH 
 
Food and Drug Administration (FDA) approved several therapies 
over the past years. Therapeutic options depend on location, 
genetic profile and stage upon the diagnosis. 
Therapeutic options may be surgical resection, chemotherapy, 
radiotherapy, photodynamic therapy (PDT), immunotherapy or 
targeted therapy [62]. 
1.6.1 Surgery 
 
Currently surgical excision is still the first approach for patients 
with the early stage disease (Stage I-IIIB), with different 
procedures depending on clinic-pathologic features of the tumor 
[62]. The resection of the lesion is generally associated with an 
excellent prognosis [63]. Primary metastatic melanoma is also 
treated with surgery alone [64], while in patients above stage IIIB 
surgery is no longer sufficient and becomes more difficult to treat, 






needing adjuvants systemic treatments to limits melanoma from 
recurring or spreading. 
1.6.2 Radiotherapy and Photodynamic therapy (PDT) 
 
Radiotherapy is considered the most effective non-surgical mode 
of locoregional therapy of melanoma, also suitable as adjuvant 
therapy after a complete excision of primary melanoma in order to 
reduce the rate of local or nodal recurrence, or as palliative 
treatment option in case of advanced or disseminated disease [65]. 
Sometimes, radiotherapy is also used in case of unsuitable major 
surgery or in case of refuse proposed surgical intervention [65]. 
Photodynamic therapy (PDT) is an effective treatment for several 
cancers (REF) and consists that in a combination of a systemic or 
local administration of photosensitizers dyes (i.e. hypericin, 
benzoporphyrin derivatives, protoporphyrin IX) in combination 
with an activating irradiation with a specific wavelength in 
presence of oxygen, generate short-lived reactive oxygen species 
(ROS) [66]. ROS generated by the treatment are responsible for 
the selective tumor destruction, tumor-associated vascular 
damage and activation of immune responses [67]. 
1.6.3 Chemotherapy 
 
Chemotherapy represents the first approved treatment option for 
advanced melanoma. Anti-tumor effects were obtained with 
Dacarbazine, platinum analogs and nitrosureas (Brahmer JR, 
Phase I study of a single-agent anti-programmed death-1 
immunologic correlates). The alkylating agent Dacarbazin was 
approved in 1974 by FDA, and used as standard chemotherapy 
medication. The effectiveness of this chemoterapeutic agent has 
been validated for several years, but only 7.5% of patients respond 
to therapy. 






Unfortunately, the single agent or synergistic treatments with 
immunotherapy or biologic agents did not improve the overall 




Cancer cells and immune system are closely related, and it is 
known that the appearance of tumors is often associated to 
presence of chronic inflammation site and infiltration of immune 
cells in the tissues. Moreover, melanoma is considered a 
particularly immuno-genic tumor, making immunotherapy of 
melanoma a dynamic field of research [31]. 
In 1995, interferon alpha 2-beta was the first immunotherapy 
approved by FDA as an adjuvant therapy for stage IIB/III 
melanoma [68] and at present, it persists in clinical trials in 
combination with targeted therapies [62]. In these cells, IFN-
alpha shows an immunomodulatory dose-dependent anti-
proliferative effect, stimulating major histocompatibility complex 
class I expression of melanoma [62]. On one hand, high-dose 
adjuvant IFN-alpha reduces the risk of recurrence in melanoma 
patients [69]. On the other, only a small percentage of patients 
respond to IFNs adjuvant treatments. 
Like IFNs, interleukin-2 (IL-2) is still included in clinical trials as 
an adjuvant therapy of chemotherapy, radiotherapy or targeted 
therapy for metastatic melanoma. This cytokine is able to expand 
effector T-cells (Teffs) and Treg populations [70], being able to 
inhibit proliferation of melanoma cells. Moreover, Joseph R.W et 
al showed in their retrospective study that patients with NRAS 
mutations better respond to high dose IL-2 therapy [71]. 
Ipilimumab is a fully human monoclonal anti-CTLA-4 antibody, 
approved for the treatment of unresectable or metastatic 






melanoma [72] and is one of the first drugs that showed survival 
benefits in this patients. Ipilimumab is able to block CTLA-4, an 
inhibitory checkpoint receptor that blocks T-cell activation and 
induces immune tolerance [62]. Blocking the inhibitory action of 
CTLA-4, Ipilimumab enhance T-cell responses, resulting in an 
higher pro-inflammatory T-cell cytokine production, and better T-
cell responses to tumor antigens, resulting in immune-mediated 
antitumor activity with an increasing T-cell expansion and 
infiltration in responding tumors [73].  
Other interesting approaches based on immunotherapy are the 
oncolytic virus and peptide vaccines. 
1.6.5 Targeted therapy 
 
Alternatively to cytostatic chemotherapy, the new concept of 
cancer therapy is focused on targeting mutated proteins that may 
control cell proliferation and malignant phenotype [62]. The 
approach uses small molecule inhibitors or antibodies that affect 
these mutated proteins, involved in the progression of the disease. 
Moreover, the advantage of the targeted therapy is the possibility 
of selecting the patients who will benefit from the treatment, 
based on the mutational profile of the tumor [62]. Interestingly, 
the identification of oncogenic driver mutations in human cancer, 
such as KRAS and BRAF, has accelerated the development of 
small-molecule inhibitors along the RAS-RAF-MEK-MAPK 
signalling pathway [46]. 
Vemurafenib offers a novel, first-line, personalized therapy for 
patients who have mutated BRAF. 
1.6.5.1 Vemurafenib 
 
Vemurafenib (chemical name: propane-1-sulfonic acid {3-[5-(4-
chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-






difluorophenyl}-amide; Commercial name Zelboraf, PLX4032) 
(Figure 6) is an orally bioavailable molecule with a low-molecular-
weight (489.93 Da), firstly synthetized in 2005 by Plexxikon (with 
the name of PLX4072) and reformulated through F. Hoffmann-
LaRoche (Basel, Switzerland) collaboration and approved by FDA 
in 2011 for the treatment of advanced BRAFV600E-positive 
metastatic melanoma [74], [75]. This BRAF-specific inhibitor 
compound is highly effective in cells with BRAFV600E mutation 
rather than the wild type, thanks to the selective binding to the 
ATP-binding pocket of the constitutively active form of BRAF 
mutated. In particular, based on the structural features of the αC 
helix and DFG position in BRAF, this molecule belongs to the 
type1/2 category of structural type inhibitors: PLX4032 is able to  
 
Figure 5. PLX4032 positioning on BRAF.  Type1/2 inhibitors is 
able to bind to the DFG “IN” position, stabilizing the αC helix in the 
“OUT” position. “Development of small molecule therapeutics and 
strategies for targeting RAF kinase in BRAF mutant colorectal 
cancer”, Adapted. 
 






bind to the active site of the kinase domain in the “DFG-in” motif 
conformation (stabilized by V600E mutation), blocking the access 
of ATP and stabilizing the αC helix in the “OUT” position (Figure 
5) [76] [49], [77].  
Co-cristallography studies of BRAFV600E with Vemurafenib 
revealed that the homologue PLX4032 is able to bind to one of the 
two BRAF promoters with 100% occupancy while the other 
promoter that is only 60% occupied by PLX4032, needs to adopt 
the DFG-out conformation, so as to interfere with the BRAF 
dimerization as a final effect [49]. The biochemical affinity of 
Vemurafenib for the mutated BRAF translates into potent 
inhibition of ERK phosphorylation only in BRAF-mutant cell lines, 
causing the arrest of the cell cycle and apoptosis in vitro, and a 
regression of the tumor growth in vivo [78]. In the phase I clinical 
trial, 80% of patients carrying the BRAFV600E mutation respond to 
PLX4032 therapy. The recommended dose of PLX4072 in clinical 
setting is 960 mg orally twice daily with a mean maximum 
concentration (Cmax) reached in the blood of 4.8 ± 3.3 µg/ml and 
an inhibitory concentration of 50% at 31 nmol/L [79]).  PLX4072 
requires 4 hrs to reach the maximum concentration after 
absorption (tmax) while the mean half-life (t ½ ) is 57 hrs [79], 
resulting in six to nine-fold accumulation between Day 1 and Day 
15 [78]. The molecule is excreted via faeces (94%) and urine (1%), 
with a clearance of approximately 30 L/day [75], [80]–[82]. 
Pharmacodinamical studies on pre- and post- treatment paired 
biopsies shows that the clinical activity of PLX4032 is effective 
when BRAF is inhibited at a level of more than 80%. Moreover, it 
was noticed that the inhibition of cytoplasmic pERK levels, but not 
inhibition of nuclear pERK levels, correlate well with tumor 
response [35], [83]. Compared to Dacarbazin chemotherapy, 
PLX4072 is able to reduce in a phase 3 trial the relative risk of 






overall and progression-free survival by 63% and 74%, 
respectively, in 675 treatment-naïve patients with the BRAFV600E 




Figure 6. Chemical Structure of Vemurafenib. 
 
1.6.5.2 Other BRAF inhibitors 
 
Dabrafenib (GSK2118436I) is another potent selective BRAF 
inhibitor, active towards BRAFV600E and also against non-
melanoma V600E BRAF-mutant cancers, including papillary 
thyroid, colorectal, ovarian. FDA approved clinical Dabrafenib 
treatment in 2013 for metastatic melanoma patients with brain 
metastasis [85]. Resistance to Dabrafenib occurrs after 6 to 7 
months from the treatment: for this reason, drug combination with 
MEK inhibitor Trametinib plus Dabrafenib is used in therapy [86]. 
Sorafenib (BAY 43-9006, Nexavar) is an orally available multi-
kinase inhibitor including wild type and V600E mutant BRAF 
[87], [88]. Moreover, this compound is able to inhibit vascular 
endothelial growth factor receptor VEGFR1, VEGFR2, VEGFR3 
and platelet-derived growth factor receptor (PDGFR-beta) [88]. 
Initially approved for the treatment of primary kidney cancer and 
advanced primary liver cancer. Sorafenib as single agent therapy 






in melanoma metastatic treatment did not show significant 
results.  
1.6.6 Resistance towards BRAF inhibitors 
 
Despite the encouraging results obtained with Vemurafenib 
treatments, most of the BRAF-mutant metastatic melanoma 
patients after 6/7 months no longer respond to therapy, and 
relapse. Long-term efficacy is thwarted due to emergence of tumor 
resistance, the principal factor for the failure of cancer therapy 
[89]. Cancer cells can become resistant under selective pressure of 
therapies (intrinsic resistance), due to the presence of preexisting 
resistant clones, or should be secondary resistant due to an 
evolving process during the treatment (acquired resistance) [47].  
Due to the extreme heterogeneity of this tumor, melanoma could 
acquire new mutations or epigenetic modifications during the 
passage from primary lesion to metastases [90]: as a result, in the 
same patient can coexist cells with susceptible BRAFV600E 
mutations together with cells that may carry different mutations 
not susceptible to BRAF inhibitions. The variety of resistance 
patterns found in individual tumors point out that each individual 
own complex defence mechanisms against toxic substances creates 
a unique resistant profile [89].  
1.6.6.1 Acquired Resistance 
 
Despite the great advances in melanoma therapy thanks to BRAF 
inhibitors, a significant proportion of BRAFV600E mutated 
melanoma does not respond to therapy, showing signs of drug 
resistance [35].  






Acquired resistance is usually due to the reactivation of upstream 
or downstream MAPK signalling pathway [91] or the reactivation 
of BRAF; otherwise it could be due to the activation of alternative 
signalling cascade like PI3K/AKT [92], or enhanced activity of 
Tirosine-Kinase Receptor (RTK) [93] (Figure 7). Notably, in case 
of acquired resistance no secondary mutations on BRAFV600E were 
found [94]. However, alternative splicing of BRAFV600E or copy 
number amplification were identified, resulting in strong 
reactivation of MEK and ERK, even in the presence of a BRAF 
inhibitor [95]. 
When BRAF is blocked, ARAF and CRAF isoform could reactivate 
the ERK signalling pathway [96] through RAS activation, 
Figure 7. Acquired resistance mechanisms in BRAFV600E 
mutated melanoma, treated with BRAF inhibitors. Acquired 
resistance in melanoma could be due to several mechanisms. Among 
these: reactivation of MAPK/ERK pathway downstream, upstream or at 
BRAF level; activation of MAPK/ERK through different isoforms of RAF 
protein; the activation of alternative pathways such as PI3K/AKT or 
COT.  






allowing the proliferation and acting as an alternative survival 
route.  
Through the ERK negative loop, BRAFV600E could partially restore 
its activity: the blockage of BRAF by inhibitors relieves ERK 
negative feedback on RAS, partially restoring RAS activity. This 
determines BRAFV600E dimerization; the binding of PLX4032 on 
one of the two component of each dimer transactivates the other 
unbound component, partially restoring the ERK pathway [97].  
Moreover, RAS mutations can allow proliferation: when RAS is 
mutated, RAS-GTP cannot return to its inactive GDP-bound state, 
becoming constitutively active. This enhances BRAFV600E 
dimerization and confers resistance to the drug [98], [99].  
Downstream, mutation on MEK1/MEK2 can overcome BRAF 
inhibition [93].  
The reactivation of BRAFV600E is mainly due to the amplification 
of the mutant BRAF allele [100] : consequently, BRAF resulted 
overexpressed. Moreover, the amplification of BRAF promotes 
BRAFV600E dimerization. In both cases, MAPK/ERK resulted 
reactivated, and BRAF inhibitors cannot compensate the 
increased BRAF expression [100]. 
Due to some points of interaction between MAPK/ERK and 
PI3K/AKT pathways, PI3K/AKT upregulation can work as a 
compensatory mechanism that can overcome BRAF inhibition and 
drive resistance [101], stimulating anti-apoptotic signals and 
increasing expression of key proliferative genes. Mutations on 
PI3K/AKT have been identified on 22% of melanomas with 
acquired resistance to BRAF inhibition [94]. 
Furthermore, PI3K/AKT pathway is activated by the binding of 
growth factors (i.e. PDGFRβ and IGF-1R) to RTKs. The 






upregulation of these receptor when BRAF is inhibited leads to a 
persistent PI3K/AKT signalling. 
PTEN negative or high basal PI3K/AKT signalling are predictive 
signals of resistance to targeted therapy agents, showing a marked 
impairment of therapy-induced apoptosis and poor therapeutic 
responses [35].  
1.6.6.2 Intrinsic resistance 
 
It is well established that BRAFV600E amplification was sufficient 
to overcome BRAF inhibition in 20% of cases [100] describing 
these patients as intrinsic resistant to BRAF inhibition [93]. 
The intrinsic resistance of melanoma to BRAF inhibition has been 
linked to mutations on different genes, that could also be related 
to the onset of acquired resistance [102]. Some of these genes are 
already classified as melanoma oncogenic drivers, i.e. loss of NF1, 
previously described in this thesis. Among the most studied genes 
is it possible to find loss of phosphatase and tensin homolog 
(PTEN), amplification of cyclin D1 (CCND1), and MAP3K8 
overexpression [93]. 
Loss of PTEN is considered one of the most frequent mutation 
responsible for intrinsic resistance, which occurs in 35% of cases 
[47]. PTEN is a tumor suppressor, negative regulator of PI3K: the 
loss of its function in patient treated with BRAF inhibitors 
determines a constitutive activation of PI3K/AKT pathway, 
leading to cellular proliferation, growth and survival [103]. 
Upregulation of Cell cycle regulator Cyclin D1, encoded by CCND1 
gene, allow cells to grow without needing BRAF pathway 
activation [93]. 
Intrinsic resistance is also related to an overexpression of 
MAP3K8, a gene that encodes for cancer Osaka thyroid oncogene 
(COT), able to  independently activate the MAPK/ERK pathway 






[104]. For this reason patients that intrinsically overexpress COT 
who are exposed to BRAF inhibitors, molecularly respond by 
producing an excess of COT, slowing cellular proliferation. This 
was confirmed by a study of Johannesen CM et al, that evidence 
that low BRAFV600E levels correlate with increased levels of COT 
[104]. 
1.7 THE MAPK SIGNALING PATHWAY 
 
The RAS-RAF-MEK-ERK mitogen-activated protein kinases 
(MAPK) pathway is an evolutionarily conserved Ser/Thr kinases 
cascade that acts like a signal transducer able to convert 
extracellular stimuli into nuclear (cellular) responses [105] such 
as growth, proliferation, differentiation, migration and apoptosis. 
The pathway is composed by a regulatory small G protein (RAS) 
and a three-tier consequently phosphorylated kinases module 
(RAF-MEK-ERK). The binding of a ligand (e.g. growth factors, 
hormones or cytokines) on the extracellular portion of a 
transmembrane tyrosine kinase receptor (RTK) is the starting 
point of the signalling cascade. Active RAS acts via adaptor 
protein to activate and recruit RAF proteins to the cell membrane 
where they are activated [1]. As a result, the conformational 
changes in RAF activate the MEK1/2 and ERK 1/2 
phosphorylation cascade until the translocation of phosphorylated 
ERK to the nucleus, where it is able to activate transcription 
factors that regulate expression of genes involved in cell growth, 
proliferation and survival [106]. Abnormalities in MAPK 
signalling helps cancer cells to acquire needful capabilities such as 
independence of proliferation signals, evasion of apoptosis, 
insensitivity to anti-growth signals, unlimited replicative 
potential, ability to invade and metastasize, attract and sustain 






angiogenesis for nutrient supply [107] and also acquire drug 
resistance and avoid oncogene induced senescence [108]. 
1.8 MITF 
 
Microphtalmia-associated transcription factor (MITF) is an 
evolutionary conserved DNA binding protein that belongs to the 
MiTF/TFE transcription factor family. All the members of this 
family share a common basic helix-loop-helix leucine zipper 
(bHLH-LZ) motif that allows to bind DNA on E-Box (CACGTG) 
and M-Box sequences and regulates the transcription of target 
genes involved in a wide range of cellular processes such as 
differentiation, proliferation, migration and senescence [109], and 
recently its function has been recognized also in the regulation of 
energy metabolism and organelle biogenesis [110]. Functionally, 
MITF binds to DNA as a dimer and it is also able to heterodimerize 
with other transcription factors member of MITF/TFE family such 
as EB (TFEB), TFE3 and TFEC [111]. 
MITF is a result of differential splicing and multi-promoter usage, 
giving rise to specific isoforms that differ in their first one or two 
exons. Some of these isoforms are tissue-restricted, suggesting 
that MITF could activate a specific subset of genes in a tissue-
specific manner [112].  MITF-M is the isoform specifically 
expressed in melanocytes, and it is considered the “master 
regulator of melanocyte biology”, due to its importance in 
melanocyte development from the neural-crest and for the 
signalling [112]. Although MITF represents a lineage-restricted 
regulator that operates in normal cells, its activity is also 
important in the molecular mechanisms of malignant cells, and its 
role as melanoma addiction oncogene was hypothesized [110]. The 
regulation of MITF-M promoter is subjected to the activation of 
different transcription factor including paired box gene 3 (PAX3), 






cAMP-responsive elements binding protein (CREB), SRY (sex-
determining region Y)-box 10 (SOX10), lymphoid enhancer-
binding factor 1 (LEF1, also known as TCF),  one  cut  domain  2  
(ONECUT-2)  and  MITF itself [112]. MITF is able to operate 
within a wide range of activity levels determining melanoma cell 
fate: high activity of MITF is related to differentiation or 
proliferation mechanisms while low activity of MITF is typical in 
stem cell-like or invasive potential [110] but also with cell 
senescence. However, evidence for the role of changes in MITF 
levels in melanoma is contradictory: in fact, high expression of 
MITF was found in melanoma relapse after combined BRAF and 
MEK inhibitor therapy [113], but resistance to targeted therapy 
has also been associated with a decrease expression of MITF [114]. 
This versatility highlights the central regulatory role of MITF in 
melanoma cell phenotype. 
1.9 METABOLIC PATHWAY 
1.9.1 An overview of Central Carbon Metabolic Pathway 
 
Central Carbon Metabolism consists of glycolysis, the pentose 
phosphate pathway (PPP), and tricarboxylic acid (TCA) cycle 
[115].  
In order to survive and to proliferate, cells needs to provide to their 
energy requirements imposed by vital processes. Normoxic, 
nonmalignant cells primarily rely on mitochondrial oxidative 
phosphorylation to generate the energy needed for cellular 
processes [116]. In presence of oxygen, a molecule of glucose is 
broken down in the cytosol through glycolysis in two molecules of 
pyruvate: after mitochondria internalisation, decarboxylation of 
pyruvate by mitochondrial pyruvate dehydrogenase (PDH) 
initiates the highly efficient process of mitochondrial oxidative 
phosphorylation (OXPHOS) [116] and the production of acetyl-






CoA feeds the tricarboxylic acid (TCA) cycle. Successive oxidation 
of acetyl-CoA into TCA cycle leads to transfer electrons to NAD+ 
to produce NADH, which in turn is consumed by oxygen-
dependent reactions producing carbon dioxide (CO2) and water 
(H2O). Moreover, NADH transfer electrons to the electron 
transport chain (ETC). The transportation of protons through the 
mitochondrial membrane is the fuel needed to generate ATP from 
ADP, finally producing 36 molecules of ATP, with oxygen serving 
as the final electron acceptor and producing water and a small 
amount of lactate as by-products. TCA cycle and OXPHOS is a 
highly efficient chemical energy conversion pathway [46], but in 
tumor mass cells rely more on less efficient glycolysis to meet their 
energy needs [115]. 
1.9.2 Glycolysis and OXPHOS in cancer cell metabolism 
 
In order to survive and proliferate, melanoma cells increase the 
glucose uptake and mostly metabolize it into lactate regardless 
oxygen levels, a process known as “aerobic glycolysis” or “Warburg 
effect” in honor of Otto Warburg, who first described the 
propensity of tumor cells to utilize glycolysis [117]. It was shown 
from Scott et al that in normoxic conditions, only 25% of pyruvate 
enters the mitochondria of melanoma cells exhibiting the Warburg 
phenotype, where it is converted in Acetyl-CoA by  pyruvate-
dehydrogenase (PDH) [117]. Warburg phenotype and metabolic 
reprogramming is also driven in part by activation of molecular 
signaling pathways, including MAPK pathway. Its activation 
causes the transcription of hypoxia inducible factor 1 alpha (HIF-
1 alpha) and stabilizing the interaction with HIF1beta. This bond 
promotes glycoyisis via transcription of LDH, aldolase and enolase 
I. 






Despite the evidence which supports the Warburg hypothesis, it is 
also necessary to consider tumor as a dynamic system, subject to 
continuous modification in response to enviromental stresses: this 
includes that metabolic networks change constantly to adapt 
cancer cell to external signals, in order to survive. 
It is known that various cancer cells are strongly addicted to other 
carbon sources such as glutamine or fatty acids: these molecules 
are oxidized by mitochondria to produce energy and/or anabolism, 
adding a mitochondrial oxidative phenotype as an alternative to 
glycolytic phenotype [118]. OXPHOS is a fundamental pathway 
required for the growth of different cancers like leukemias, 
prostate, breast cancer and also melanoma [46]. Barbi de Moura 
et al showed through bioenergetics analysis that metastatic 
melanoma in vitro had an high level of OXPHOS in addition to 
glycolysis [119]. 
1.9.3 Lactate production and its importance in melanoma 
metabolism 
 
Lactate is the end product of glycolytic pathway, in order to 
maintain NAD+, lactate is secreted from the cell primarily through 
monocarboxylate transporters (MCTs), with MCT4 as the most 
significant transporter. 
It was demonstrated that a higher expression of GLUT1 and 
MCT4 transporters are closely related to tumor progression, 
pointing out that Warburg Phenotype and lactate secretion 
cooperate to promote melanoma metastasis [120]. The release of 
lactate into the tumor microenviroment (TME) determines drastic 
alterations facilitating angiogenesis, promoting metastasis and 
suppressing immune system [115], and the release of protons 
produced via dissociation of lactic acid contributes to lower the pH 
of extracellular space  [115]. The acidification of pH is also due to 






additional membrane protein complexes like carbonic anhydrase 
IX (CAIX), sodium-bicarbonate transporter 1, and anion 
exchanger 2 (AE2). 
1.9.4 MAPK/ERK pathway and metabolism 
 
Oncogenic mutation largely contributes to the reprogrammation of 
the metabolic profile that influences cancer cell fate, sustaining 
cell survival and proliferation regardless external conditions. 
Some of these were identified in melanoma, including BRAF, 
NRAS, KIT, GNAQ, GNA11, NF1 and telomerase [121], and most 
of them, including are able to activate MAPK/ERK pathway. 
In the context of BRAF-MEK-ERK signalling, mutant BRAF 
exhibits an increased expression of glucose transporters as well as 
glycolytic genes, resulting in a glycolytic phenotype with inhibition 
of oxidative phosphorylation [118], [122]. Cellular reprogramming 
through BRAFV600E overexpression causes modification in the 
expression of numerous metabolic genes, such an increasing in 
lactate dehydrogenase A (LDHA) and pentose phosphate pathway 
enzymes [50]. This evidence indicates that glucose metabolism 
could be important for BRAF-driven tumorigenesis. 
1.9.5 BRAF inhibitors and metabolism 
 
The metabolic effect of the inhibition of MAPK pathway in tumor 
cells is the reduction in glucose utilization and in the glycolytic 
flux, resulting from the regulation of the glycolytic regulator 
HIF1α and MYC. 
Moreover, it is demonstrated that BRAFV600E inhibition is able to 
suppress uptake of radioactive glucose tracer 2[18F]fluoro-2-
deoxy-d-glucose (FDG) in BRAFV600 human melanoma cells and 
xenografts [123] and in patients with BRAFV600E melanoma, 






suggesting that the inhibition of glycolysis could be important for 
clinical response to BRAFi [124]. 
2 AIM OF THE WORK 
 
Understanding cancer relapse development requires an indepth-
study of the processes underlying cancer drug resistance. The 
causes behind this phenomenon are multi-fold and often include 
different mechanisms including drug efflux, target alteration, 
drug degradation, epithelial mesenchymal transition, immune 
system evasion and enhanced or alternative metabolism [125]. 
Moreover, the development of drug-resistant tumors further 
modifies the phenotypic behavior of cancer. This is also made more 
complex by the heterogeneity of the patient’s response to the 
therapy, highlighting the need to find personalized therapies 
based on the pattern of patient’s specific tumor. 
Among the latest therapeutic strategies adopted for the treatment 
of tumors, it is possible to find target molecules which focus on 
targeting mutated proteins in order to shut down specific altered 
pathways. However, the problem arises when cancer cells express 
a pattern of resistance mechanisms able to constitutively activate 
oncogenes which can support cell survival [125]. In this regard, 
BRAFV600E mutated melanomas show a constitutive activation of 
the MAPK pathway cascade that promotes cell growth [126]. 
Patients with unresectable metastatic BRAFV600E tumors are 
treated with BRAFV600E inhibitors (Vemurafenib, Dabrafenib), 
alone or in combination with MEK-ERK inhibitors (Trametib), in 
order to switch off the survival pathway. Despite this pathway 
being a target-model for selective therapy, the tumor is able to 
overcome BRAF inhibition through the reactivation of the MEK-
ERK cascade or the upregulation of alternative signalling 






pathways. Although the tumor initially responds to BRAFV600E 
inhibitors, the use of the drug progressively decreases the tumor 
dependence on the pathway, and the chronic treatment with the 
inhibitor determines the activation of alternative pathways, also 
in combination with other drugs.  
However, the clinical response of patients to the treatments is not 
unique, so it is crucial to identify the specific features that can 
predict the effectiveness of the treatment on the subset of patients. 
According to the principle of personalized medicine, based on the 
identification of specific markers and mutations that allow  the 
formulation of increasingly effective therapies [127], it is 
necessary to improve the in vitro models in order to obtain more 
information on the in vivo different responses. 
In order to overcome drug resistance and design personalized 
therapy, it is important to better identify the heterogeneous 
survival mechanisms directly using experimental models that can 
reflect clinical conditions and tumor responses. In this context, our 
research group selected a multi-drug resistant model of a human 
MYCN-amplified neuroblastoma (NB) cell line in order to 
investigate the molecular mechanisms responsible for Etoposide 
resistance [128]. In this previous study, NB-resistant cells, after 
chronic treatment with Etoposide, were shown to have a major 
oxygen consumption and an increased oxidative phosphorylation 
in respect to the non-resistant counterparts. Based on these 
findings, understanding the role of metabolism   in drug- 
resistance is crucial to establish a therapeutic approach in cancer 
treatment.  
In the current thesis, the main aim was to select a human 
metastatic melanoma BRAFV600E mutated cell line after a long-
term treatment with PLX4032 in order to obtain an in vitro model 
for studying the mechanisms of PLX resistance. Herein, the 






phenotypic changes and the metabolism of this PLX-resistant 
melanoma cell line were investigated to identify “metabolic 
strengths” that must have taken into account to fight melanoma 
malignancy and relapse.  
  






3 MATERIAL AND METHODS 
3.1 MODEL SYSTEMS 
3.1.1 Cell lines 
 
All the experiments in this thesis have been performed using a 
human cell line, derived from patient biopsies, growing as two-
dimensional mono-cultures. Optimization of cell densities was 
performed for all test conditions, since over-confluent cell cultures 
can lead to underestimation of cell proliferation, signaling and 
drug efficacy [129], [130]. 
In detail, MeOV Human melanoma cell line was kindly donated 
from Dr. Gabriella Pietra (University of Genoa, Genoa, Italy), 
established directly from the biopsies of an untreated patient and 
maintained in RPMI 1640 medium supplemented with 10% Fetal 
Bovine Serum (FBS, Euroclone Spa, Pavia, Italy), 1% L-Glutamine 
(Euroclone) and 1% Penicillin/Streptomicin (Euroclone) and grown 
in standard conditions (37°C humidified incubator with 5% CO2). 
3.1.2 Generation of chemo-resistant subclones and 
certification of autenthicity of the lines 
 
The MeOV PLX-Resistant (PLX-R) and dimethyl sulfoxide -
Resistant (DMSO-R) subclones were gradually selected by 
treating MeOV cell line with increasing concentrations of 
PLX4032 (Selleckchem, Texas) or DMSO, used to solve PLX, as 
control. The DMSO-R subclone is PLX-Sensitive, and it is used as 
a comparative model in order to exclude a toxic effect of DMSO 
chronic treatment, and a potential interference with the effects 
exerted by PLX chronic exposure. 
In details, sub-confluent cells were initially treated with 250 nM 
of the drug for 72 hrs. Then, drug was removed and cells were 
allowed to recover (according to [131], this procedure is defined as 






“recovery time” of this cell line). Upon recovery, cells were again 
treated with the same concentration of the drug for 3 times, before 
increasing the concentration of the drug. This process was 
repeated for a period of 6 months, to generate resistant cell lines, 
reaching the concentration of 1.5 µM PLX and 0.0075% v/v DMSO. 
The culture medium was changed once a week and cells were 
seeded at 1.5 x 106 density twice a week.  
To certify the authenticity of these lines, Short Tandem Repeat 
(STR) profile of MeOV DMSO-R and PLX-R was carried out by 
U.O. Service of Immunoematology and Trasfusional, Ospedale 
Policlinico San Martino. Fifteen highly polymorphic STR loci plus 
amelogenin (Cell IDTM System, Promega, Milan), were used. 
Detection of amplified fragments was obtained by ABI PRISM 
3100 Genetic Analyzer. Data analysis was performed by 
GeneMapper® Software version 4.0 (Thermo Fisher Scientific, 
Waltham, MA, USA),  
3.1.3 Treatments 
 
MeOV PLX-R and DMSO-R cells were treated with 1.5 µM of 
PLX4032, (Selleckem) or 0.0075% v/v DMSO (Santa Cruz) for 24, 
48 and/or 72 hrs, depending on the experiment. Cell cultures were 
carefully inspected before and during the experiments to be sure 
that cell density was optimal (samples were discarded if cell 
confluence reached > 90%). 
3.2 EXPERIMENTAL PROCEDURES 
 
3.2.1 Cell Viability (MTS) Assay 
 
In order to test cell viability, 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) 
CellTiter 96 Acqueous One Solution Cell Proliferation Assay 






system (Promega) was performed according to the manufacturer’s 
instructions.  
MTS is able to measure the activity of living cells via 
mitochondrial dehydrogenases. Briefly, 1 x 104 cells MeOV PLX-R 
and MeOV DMSO-R cells were seeded in 96-well plates (Corning) 
and allowed to adhere overnight. The following day, cells were 
treated with increasing concentrations (0.01, 0.05, 0.1, 0.5, 1.5, 5, 
10 and 20 µM) of PLX4032 or corresponding volume of DMSO, and 
then cells were left to grow for 72 hrs. Next, 20 µl of Cell Titer 
Aqueous One Solution were added for one hour in standard 
conditions (37°C in humidified incubator with 5% CO2). The 
conversion of tetrazolium to tetrazane takes place only in living 
cells, and the amount of intracellular formazan can be measured 
spectrophotometrically. Absorbance was detected at 490 nm using 
a BioRad iMark microplate reader (BioRad, Milano). Six replicate 
wells per concentration were used to quantify cell viability.  
The increase in resistance, known as fold resistance is calculated 
through the following equation [131]: 
𝐹𝑜𝑙𝑑 𝑅𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑐𝑒 =
𝐼𝐶50 𝑜𝑓 𝑅𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑡 𝐶𝑒𝑙𝑙 𝐿𝑖𝑛𝑒 (𝑃𝐿𝑋 − 𝑅)
𝐼𝐶50 𝑜𝑓 𝑃𝑎𝑟𝑒𝑛𝑡𝑎𝑙 𝐶𝑒𝑙𝑙 𝐿𝑖𝑛𝑒 (𝐷𝑀𝑆𝑂 − 𝑅)
 
 
3.2.2 Clonogenic Assay 
 
Clonogenic assay is an in vitro method useful that determines the 
effectiveness of drug treatment on tumorigenicity, by evaluating 
the capacity of single cell to produce colonies.  
2 x 102 MeOV PLX-R and MeOV DMSO-R cells were seeded in 6-
well plates (Corning), and allowed to adhere overnight. Cells were 
treated with 1.5 µM PLX4032 or with the corresponding dose of 
DMSO for 24 hrs, then medium was changed and cells were 
maintained in a drug-free medium for 15 days. Plates were fixed 






with ice-cold methanol stained with crystal violet dye solution 
(0.5% H2O in 50% Methanol), and colonies consisting of 30 or more 
cells were counted with an inverted microscope. Images of the 
colonies were acquired with a digital camera (Huawei P20 PRO).  
3.2.3 Wound Healing Assay 
 
Wound healing assay is an in vitro method that allow to study 
quantitatively the directional cell migration in vitro, making a 
scratch on a cell monolayer and measuring the wound closure by 
comparison of the images captured at regular intervals. 
3x105 cells were seeded in 12 well plates (Corning), and let them 
grow. At 95% of confluency, cells were starved with RPMI-1640 
supplemented with 0.2% FBS to avoid cell growth. After 24 hr, 
media was discarded and 1 ml of PBS for each well was added. An 
artificial wound in the cell monolayer was created using a 200 µl 
pipette tip and then the monolayer was washed with PBS once. 
Drug-free medium or 1.5 µM PLX4032 or DMSO medium was 
added to each well. The migration distance was photographed 
through an inverted phase microscope (x10) at zero time and after 
24 and 48 hr from the treatment. The rate of closure of the wound 
recovery was determined using Image J software (National 
Institute of Health, Bethesda, MD, USA).  
3.2.4 Intracellular ROS production assay 
 
ROS generation was measured by the use of H2DCFDA (2′-7′-
dichlorofluorescin diacetate) assay. H2DCFDA is a non –
fluorescent compound, which after diffusion into the cells, is 
deacetylated by cellular esterases to 2’,7’-dichlorofluorescein 
(H2DCF) that, in presence of ROS, is converted in the oxidized 
higly-fluorescent molecule DCF which can be detected by 






fluorimetric analysis. The generated fluorescence intensity are 
proportional to the ROS amount.  
1 x 104 cells MeOV PLX-R and MeOV DMSO-R cells were seeded 
in 96-well plates (Corning), and allowed to adhere overnight. The 
following day, cells were treated 1.5 µM PLX, and incubated for 72 
hrs. After treatments, cells were washed with PBS and stained 
with DCFDA (Thermofisher Scientific) for 30 min at 37°C. Then, 
cells were incubated with 90% DMSO for 10 min in the dark with 
shaking [132]. Fluorescence at 485 nm excitation/520 nm emission 
was measured. Values were normalized to the protein content and 
expressed as a % of the fluorescence relative to the untreated 
control. 
3.2.5 Metabolic Analysis 
 
8 x 105 cells were seeded in 10 cm dishes and treated for 72 hrs as 
above described. Cells were tripsinized and counted, and cell 
culture medium was collected. The media were assayed for 
measuring the lactate level, while the cells were used for other 
metabolic evaluations. All the measurements were normalized to 
cell number. 
3.2.5.1 Oxygen Consumption Analysis 
 
Oxygen (O2) consumption (OCR) was measured by a 
thermostatically controlled (25°C) oxygraph apparatus equipped 
with an amperometric electrode (Unisense-Microrespiration, 
Unisense A/S, Denmark).  For this experiment, 2x105 cells were 
permealised with 0.03 mg/ml digitonin for 1 min, centrifuged for 9 
min at 1000 rpm and resuspended in an appropriate buffer 
containing: 137 mM NaCl, 5 mM KCl, 0.7 mM K2PO4 and 25 mM 
Tris HCl pH 7.4. To stimulate complexes I, III and IV pathway, 10 
mM pyruvate plus 5 mM malate were added. 20 mM succinate was 






added to stimulate the pathway composed by complexes II, III and 
IV. In order to verify whether OCR is due to electron transport 
chain, 0.1 mM rotenone or 50 µM antimycin A, specific inhibitors 
of complex I or complex III, were used to block the first and the 
second pathway, respectively  [133], [134]. 
3.2.5.2 Evaluation of intracellular ATP and AMP Levels 
 
ATP and AMP levels were measured by the enzyme coupling 
method, following NAD(P)/NAD(P)H reduction/oxidation at 340 
nm. The ATP concentration was measured in a medium containing 
100 mM Tris–HCl, pH 7.4, 5 mM MgCl2, 50 mM glucose, 0.2 mM 
NADP. The assay started after the addition of 4 µg of purified 
hexokinase and 2 µg of glucose-6-phosphate dehydrogenase.  
AMP concentration was measured using a buffer containing 100 
mM Tris–HCl, pH 7.4, 5 mM MgCl2, 10 mM phosphoenolpyruvate, 
0.15 mM NADH, 0.2 mM ATP. The assay started after the addition 
of 4 µg of purified kinase plus lactate dehydrogenase and 2 µg of 
adenylate kinase [135]. 
3.2.5.3 ATP synthase activity assay 
 
To evaluate ATP synthesis through Fo-F1 ATP synthase, 1x105 
cells were incubated in a specific buffer containing 10 mM Tris-
HCl pH 7.4, 100 mM KCl, 5 mM KH2PO4, 1 mM EGTA, 2.5 mM 
EDTA, 5 mM MgCl2, 0.6 mM ouabain and 25 mg/ml ampicillin, for 
10 min at 37 °C. Afterword, 10 mM pyruvate/5 mM malate or 20 
mM succinate were added to induce ATP synthesis through the 
activation of the complex I, III, IV or the complex II,III,IV 
pathways, respectively. The reaction was monitored for 2 min, 
every 30 sec, by the luciferin/luciferase chemiluminescent method 
and using a GloMax® 20/20n Luminometer (Promega Italia, 
Milano, Italy). ATP standard solution between 10-8 and 10-5 M 






(luciferin/luciferase ATP bioluminescence assay kit CLSII, Roche, 
Basel, Switzerland) were used. Data were expressed as nmol ATP 
produced/min/106 cells [133]. 
In order to evaluate the oxidative phosphorylation efficiency, the 
P/O ratio was calculated and expressed as the ratio between the 
concentration of the produced ATP and the amount of consumed 
oxygen in the presence of respiring substrate and ADP. In 
physiological conditions, when the oxygen consumption is over, 
P/O ratio should be around 2.5 and 1.5 after pyruvate/malate or 
succinate addition, respectively [136]. 
3.2.5.4 Glucose Consumption Analysis 
 
Glucose consumption was evaluated following the reduction of 
NADP at 340 nm, through the hexokinase (HK) and glucose-6-
phosphate dehydrogenase (G6PD) coupling system. The assay 
buffer contained 100 mM Tris-HCl, pH 7.4, 2 mM ATP, 10 mM 
NADP, 2 mM MgCl2, 2 IU of hexokinase, and 2 IU of glucose-6-
phosphate dehydrogenase (G6PD). Data were normalized on cell 
number and expressed as mM glucose consumed/106 cells [137]. 
3.2.5.5 Lactate Release Analysis 
 
Extracellular lactate concentration was measured in the growth 
medium by spectrophotometry following the reduction of NAD+ at 
340 nm. Samples were suspended in an appropriate buffer 
containing 100 mM Tris-HCl (pH 8), 5 mM NAD+ and 1 IU/ml of 
lactate dehydrogenase.  Samples were analysed before and after 
the addition of 4 µg of purified lactate dehydrogenase [137].  Data 
were normalized per number of cells and expressed as mM lactate 
released/106 cells. 
 






3.2.6 Protein Extraction and Quantification 
 
After treatment with PLX4032 or DMSO, medium mas removed 
and then rinsed once with PBS at RT. Then cells were harvested 
with ice-cold Scraping Buffer pH 7.2 [50 mM Tris-HCl, 150 mM 
NaCl, 2 mM EDTA, 1 mM EGTA, 1 mM NaF, 1 mM PMSF, 1% 
Triton and 1% Protease inhibitor Cocktail III], scraped and the 
lysate was passed through 25-gauge needle, maintained in ice. The 
lysates were centrifuged at 15000 RPM x at 4°C for 10 min, and 
then the supernatants were transferred in new tubes and stored 
at -80°C.  
Protein concentration was determined using the PierceTM BCA 
protein assay kit (Thermofisher, USA) following manufacturer’s 
instruction. 
3.2.7 Western Blotting and Antibodies 
 
Protein aliquots were mixed with 3.5x loading dye [62.5 mM Tris-
HCl, pH 6.8, 2% SDS, 25% glycerol, 0.01% bromophenol blue], 
heated at 95°C for 5 min, separated on 10% or 12% Mini-
PROTEAN® TGXTM Precast Gels along with protein marker 
(Sharpmass VI, Euroclone) and then transferred to PVDF 
membrane (GE Healthcare, Amersham). 
Non-specific binding sites were blocked by incubating membrane 
in 5% dry non-fat milk in PBS-Tween (80 mM Na2PO4, 20 mM 
NaH2PO4, 100 mM NaCl, 0.1% Tween 20) for 1 hr at RT. Then 
membrane were incubated overnight  using rabbit antibody anti 
p44/42 MAPK (Erk1/2) and anti Phospho-p44/42 MAPK (Cell 
Signaling Technology Inc., Danvers, MA, USA Upstate, Lake 
Placid , NY, USA), Phospho-p44/42 MAPK, MITF,GAPDH), anti 
MITF (Abcam, Cambridgeshire, UK) and GAPDH (Santa Cruz 
Biotechnology Inc, Santa Cruz, CA, USA) .Membranes were 
washed 3x in TBS-Tween (20 mM Trizma base, 0.5 M NaCl, 0.1% 






Tween 20) and then incubated for 1 hr with the suitable HRP-
conjugated secondary antibody (GeHealthcare, Buckingamshire 
UK). The signal was detected using ECL detection kit (Pierce™ 
ECL Western Blotting Substrate, ThermoFisher) and analysed 
with an image densitometer connected to Quantity One Software 
(Bio-Rad Laboratories, Hercules, CA, USA). 
3.2.8 Mitochondrial membrane potential analysis 
 
Mitochondrial membrane potential is evaluated by staining cells 
with tetrametilrhodamine (TMRM), a fluorescent cell-permeant 
dye that accumulates in mitochondria proportionally to 
mitochondrial membrane potential [138]. The fluorescence 
intensity is quenched when the dye is accumulated within the 
matrix of mitochondria. 1.5 x 104 DMSO-R and PLX-R cells were 
seeded on chamber slides (Lab-Tek, Thermo Fisher Scientific Inc, 
75 Panorama Creek Drive, Rochester, NY), and let adhere 
overnight. Cells were treated with 1.5 µM PLX4032 or DMSO for 
72 hrs. Then, cells were washed once with PBS and stained with 
100 nM TMRM in phenol-red-free RPMI 1640 supplemented with 
1% v/v FBS for 40 min at 37°C, 5%CO2. Forward, the media was 
replaced for imaging. Images were acquired using an (Leica 
TCSSP, Nussloch GmbH) microscope and processed using ImageJ 
software (NIH, USA). 
3.2.9 Confocal Microscopy analisys of MITF 
 
1.5 x 104 DMSO-R and PLX-R cells were seeded on chamber slides 
(Lab-Tek) and let adhere overnight. Cells were treated with 1.5 
µM PLX4032 or DMSO for 72 hrs. Then, cells were washed once 
with PBS and fixed with ice-cold Methanol. Cells were washed 
again and nonspecific binding sites of the cells were blocked by 
incubation in 1% BSA in PBS for 1 hr. Then cells were incubated 
with MITF primary antibody (Abcam). Cells were washed twice 






PBS and incubated with secondary antibody Alexa Fluor 688 + 
TOPRO to counterstain nuclei. The glass was fixed with Mowiol. 
Images were acquired using an (Leica TCSSP, Nussloch GmbH) 
microscope and processed using ImageJ software (NIH, USA) 
3.2.10 Statistical Analysis 
 
Statistical analysis was performed by using GraphPad Prism 6 
(San Diego, USA), using one-way ANOVA test with Bonferroni 
post hoc test to determine the statistical significance of observed 
differences. All data are shown as mean ± standard error mean 
(SEM) from at least three independent experiments, conducted in 
triplicates. p values < 0.05 were considered significant. 
  







4.1 CHRONIC PLX4032 EXPOSURE INDUCES A 
PLX4032-RESISTANT PHENOTYPE IN MEOV CELLS 
 
The chronic treatment of BRAF-mutated melanoma with 
PLX4032 can lead to melanoma progression and resistance to 
apoptosis. In order to investigate the effects of PLX4032, a 
BRAFV600E-mutated human metastatic melanoma cell line 
(MeOV), isolated from a patient, was treated for 6 months with 
increasing concentrations of PLX4032 (1 nM-1.5 μM) and then 
maintained in culture with the same drug at the highest 
concentration. In all experiments, it should be noted that the 
chronically-PLX4032-treated cells (PLX-R) were compared to the 
chronically-DMSO-treated ones (DMSO-R). 
The identity of melanoma cell lines was verified and certified, 
comparing MeOV parental cell line profile to the two profiles of 
resistant cell lines. As shown in Figure 8, the results demonstrated 
an identical profile of STR sequence loci in all MeOV cell lines, 
certifying the authenticity of selected cells and demonstrating lack 
of contamination from other cell lines and microbes. 
 
Figure 8. STR profile of MeOV parental (NT), DMSO-R and PLX-
R cell lines. All Me OV cell lines showed an identical STR profile. 
To evaluate the state of drug resistance, PLX-R and DMSO-R cells 
were exposed to increasing concentrations (0.1-20 μM) of PLX4032 
for 72 hrs. As shown in Figure 9A, PLX4032 was cytotoxic for 
DMSO-R cells in a dose-dependent manner (IC50: 0.5 μM) 
whereas the cytotoxic effect with a 22% reduction of cell viability 






was recorded in PLX-R cells at the concentration of 5 μM, reaching 
IC50 at 18 μM.  
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Figure 9. MeOV cells chronically exposed to PLX4032 develop a 
resistant phenotype. Cell viability was evaluated by MTS assay in 
PLX-R and in DMSO-R exposed to increasing concentrations (0.1 µM-1.5 
μM) of PLX4032 (A) or DMSO (A) for 72 hrs. The graph summarizes 
quantitative data of the means ± SEM of four independent experiments. 
(** p <0.01; **** p < 0.0001 vs. respective Ctr) 
 






According to equation [131] shown in Materials and Methods, 
PLX-R showed a 36-fold increased resistance to PLX4032 in 
comparison with DMSO-R. Notably, the same volume of DMSO 
utilized to dissolve PLX4032 at all concentrations tested, did not 
affect per se the survival of both cell lines (Fig. 9B). 
 
4.2 THE ACQUISITION OF PLX4032 RESISTANCE IS NOT 
CONSEQUENTIAL TO THE REACTIVATION OF ERK 
PATHWAY AND DOES NOT INVOLVE MITF. 
 
Since PLX4032 resistance is classically mediated by MAPK/ERK 
reactivation [92], the state of ERK activation was investigated. As 
shown in Figure 10, 24 hr treatment with PLX4032 or DMSO 
treatment (1.5 µM) did not change ERK protein expression levels 
in comparison to untreated cells. Instead, the same treatments 
drastically reduced pERK levels in DMSO-R, demonstrating that 
PLX4032 was able to exert an inhibitory effect on the V600EBRAF 
mutation. Unexpectedly, both untreated and acutely-treated PLX-
R cells showed low pERK levels (Figure 10), indicating that the 
acquisition of resistance in this cell line is not effectively due to 
the classical reactivation of the MAPK/ERK pathway.   
 
Figure 10. The acquisition of PLX4032 resistance is not dependent 
on ERK reactivation. Protein levels of ERK and p-ERK in DMSO-R 
and PLX-R cells treated for 24,48 and 72 hrs with 1.5 μM PLX4032. 
Immunoblots shown are representative of three independent experiments. 
GAPDH is the internal loading control 






However, since MITF is a downstream effector of ERK and it is 
involved in regulating melanocyte growth and motility [139] its 
role was investigated. Confocal microscopy shows that in basal 
conditions both cell populations expressed MITF protein (Figure 
11A), and acute treatment with DMSO or PLX did not change 








Figure 11. PLX4032 resistance did not involve MITF expression. 
PLx-R and DMSO-R cells were stained with MITF antibody and 
counterstain with ToPRO.(A.) Protein level of MITF in DMSO-R and 
PLX-R cells treated for 24,48 and 72 hrs with 1.5 µM PLX4032. 
Immunoblots shown are representative of three independent experiments. 
GAPDH is the internal loading control (B.) 






In addition, the clonogenic and the migratory ability of melanoma 
cells were analyzed. As shown in Figure 12, DMSO-R cells had 
greater capacity to form colonies in comparison to PLX-R (41 
colonies vs. 2.25 respectively). Notably, acute DMSO treatment 
did not induce changes in the colony formation in either cell line 
whereas acute PLX exposure enhanced the number of colonies in 
DMSO-R cells by 90% (75 vs. 41 colonies). The number of colonies 
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Figure 12. Clonogenic potential of DMSO-R and PLX-R cells. The 
ability to form colonies of DMSO-R and PLX-R cells is analyzed by using 
an anchorage-independent clonogenic assay (A). Histogram summarizes 
quantitative data of means±SEM of three independent experiments (B) 
(*** p = 0.0001 vs. Control) 
The results obtained by the wound healing assay showed that 
untreated DMSO-R cells efficiently restored the monolayer after a 
maximum of 72 hrs, and 24 hr PLX treatment did not modify their 
migration rate (Figure 13A). On the contrary, the wound-closure 






ability of untreated and PLX-treated PLX-R cells was significantly 
inhibited, suggesting that the acquisition of resistance determines 
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 Figure 13. PLX4032 treatment reduces the migratory activity of 
PLX-R cells. Cell migration of DMSO-R (A) and of PLX-R (B) was 
evaluated by the scratch assay. The rate of migration was quantified by 
measuring the distance between the migrating cell boundaries. 
Histogram summarizes quantitative data of means ± SEM of three 
independent experiments (** p < 0.01, **** p < 0.0001) 
 






4.3 THE ACQUISITION OF PLX4032 RESISTANCE 
CONFERS TO MELANOMA CELLS THE ABILITY TO 
MAINTAIN AN EFFICIENT OXPHOS METABOLISM 
 
It has been reported that MITF is also involved in cancer metabolic 
reprogramming [140] since it can control mitochondria biology 
and, although it is not directly involved in glucose uptake, it 
stimulates OXPHOS metabolism [140].  As shown in Figure 14, 72 
hr PLX4032 exposure did not alter either mitochondria 
morphology and mitochondria membrane potential of PLX-R cells. 
In fact, untreated and treated PLX-R cells had elonged 
mitochondria organized in a functional reticulum whereas DMSO-
R cells, after the same treatment, underwent a loss of 
mitochondria organization and a reduction in mitochondria 
membrane potential (Figure 14). 
 
Figure 14. Confocal microscopy analysis of mitochondria 
morphology and membrane potential in DMSO-R and PLX-R 
cells. PLX-R and DMSO-R cells were treated with 1.5 µM PLX4032 for 
72 hrs. After treatment, cells were fixed, permeabilized and stained with 
tetramethilrodamine (TMR). The figures shown are representative of the 
experiments performed in triplicate. 






However, the changes in mitochondria morphology and potential 
observed in PLX-treated DMSO-R cells were not accompanied by 
alterations of ROS production (Figure 15). 
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Figure 15. ROS production in DMSO-R and PLX-R cells. ROS 
production was analyzed in DMSO-R (A) and in PLX-R (B) cells 
incubated for 24, 48 and72 hrs with PLX4032 (1.5 or 5 μM). Histograms 
summarize quantitative data of the means ± S.E.M. of three independent 
experiments. (**p<0.01 vs. respective Ctr) 
 






Only a 20% increase of ROS production was observed in PLX-R 
cells after 72 hrs of PLX exposure (Figure 15). 
To investigate the role of cell metabolism in the acquisition of drug 
resistance, the oxygen consumption rate (OCR) and ATP synthesis 
were analyzed in both cell lines and under all experimental 
conditions. 
In basal conditions, OCR and the ATP synthesis of DMSO-R were 
25% higher than the values measured in PLX-R cells (Figure 16 A 
and B). Moreover, both parameters were not influenced by DMSO 
treatments in both cell line populations (Figure16 A and B).  
Moreover, in DMSO-R cells, PLX4032 exposure reduced OCR and 
ATP synthesis in a time-dependent manner. In particular, in 
comparison to untreated cells, the Complex-I linked OCR was 
reduced by 10%, 21% and 57% after 24, 48 and 72 hrs, respectively 
and the Complex-II linked OCR decreased by 8%, 16% and 42% 
respectively. ATP synthesis was reduced by 13%, 30% and 47% in 
Complex-I after 24, 48 and 72 hrs, respectively and 12%, 35% and 
58% in Complex-II respectively (Figure 16 A and B). The same 
treatments did not induce alterations of OCR and ATP synthesis 
in PLX-R cells (Figure16 A and B).  
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Figure 16.Evaluation of oxygen consumption rate and ATP 
synthesis in DMSO-R and PLX-R cells. The ability of cells to consume 
oxygen and to produce ATP by OXPHOS was evaluated using complex I-
linked substrates (pyruvate, malate) and complex II-linked substrate 
(succinate), that are physiological substrates stimulating the 
mitochondrial OXPHOS. The oxygen consumption rate (OCR) (A) was 
evaluated in untreated and in 1.5 μM PLX4032-treated (24, 48 and 72 
hrs) DMSO-R and PLX-R cells. Results were reported as nmol 
O2/min/106 cells. B. ATP synthesis was measured in untreated and in 
1.5 μM PLX4032-treated (24, 48 and 72 hrs) DMSO-R and PLX-R cells. 
Results were reported as nmol ATP/min/106 cells.  
Histograms summarize quantitative data of means ± S.E.M. of three 
independent experiments (*p< 0.05 vs. respective Ctr ; **p< 0.01 vs. 
respective Ctr; ****p< 0.0001 vs. respective Ctr). 
 
Moreover, in order to evaluate the oxidative phosphorylation 
efficiency, the P/O ratio was calculated and expressed as the ratio 
between the concentration of the produced ATP and the amount of 
consumed oxygen in the presence of respiring substrates and ADP. 
Under physiological conditions, when the oxygen consumption is 
over, P/O ratio should be around 2.5 and 1.5 after pyruvate/malate 
or succinate addition, respectively [141]. 






As shown in Table1, in untreated and DMSO-treated DMSO-R 
cells, the P/O ratio was comparable to the physiological level (2.5 
for Complex I and 1.5 for Complex II) reported by Hinkle [141]. In 
addition, after 72 hr PLX4032 exposure, the P/O ratio was reduced 
by 21.6%, suggesting a partial OXPHOS uncoupling. In PLX-R 
cells all treatments did not induce alterations of P/O ratio which 
was always maintained at the physiological levels (Table 1). 
 
DMSO-R P/O Ratio      
  24 hrs 48 hrs 72 hrs 
  
Complex I Complex II Complex I Complex II Complex I Complex II 
Ctr 2.43±0.03 1.45±0.04 2.43±0.06 1.47±0.08 2.41±0.06 1.45±0.04 
DMSO 2.47±0.03 1.46±0.05 2.43±0.05 1.50±0.07 2.44±0.02 1.46±0.01 
PLX 1.5 µM 2.44±0.10 1.55±0.21 2.26±0.01* 1.35±0.04* 1.96±0.21* 1.16±0.13* 
       
PLX-R P/O Ratio      
  24 hrs   48 hrs   72 hrs   
  Complex I Complex II Complex I Complex II Complex I Complex II 
Ctr 2.42±0.06 1.65±0.09 2.44±0.09 1.58±0.10 2.42±0.05 1.55±0.14 
DMSO 2.48±0.14 1.57±0.14 2.41±0.05 1.55±0.12 2.44±0.09 1.55±0.15 
PLX 1.5 µM 2.41±0.11 1.57±0.14 2.39±0.08 1.60±0.14 2.46±0.06 1.70±0.32 
 
Table 1. PLX-R cells maintain an efficient OXPHOS after acute 
PLX4032 exposure. P/O ratio values after PLX4032 and DMSO 
treatments of DMSO-R and PLX-R cells, calculated and expressed as the 
ratio between the concentration of the produced ATP and the amount of 
consumed oxygen in the presence of respiring substrates and ADP 
(*p<0.05 vs. respective Ctr) 
In addition, as shown in Figure 17, untreated DMSO-R and PLX-
R cells had comparable intracellular ATP and AMP levels, at all 
three considered timepoints (24, 48 and 72 hrs) and DMSO 
exposure did not influence these parameters. In conformity with 
the results above reported, PLX4032 treatment affected in a time-
dependent manner ATP and AMP levels of DMSO-R cells. In fact, 






ATP levels were reduced by 10%, 21% and 57% after 24, 48 or 72 
hrs respectively, in comparison to untreated DMSO-R cells (Figure 
17 A), while AMP levels increased by 13%, 30% and 47% (Fig. 16, 
C). In PLX-R cells all treatments did not induce changes in ATP 
levels (Figure 17 B) and only 72 hr-exposure to PLX4032 was able 
to increase the intracellular levels of AMP by 14% in comparison 
to untreated cells (Figure 17 D). Accordingly with these findings, 
the ATP/AMP ratio was reduced by 33%, 40% and 70% in 24, 48 
and 72 hr PLX-treated DMSO-R cells (Figure 17 E) whereas it was 
not modified in PLX-R until 48 hrs of PLX treatment with a 10% 
reduction after 72 hrs (Figure 17 F).  
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Figure 17. PLX-R cells maintain the energetic status after PLX 
exposure. ATP (A,B), AMP (C,D) and ATP/AMP ratio (E,F) were 
evaluated in untreated and in PLX-treated DMSO-R (A) and PLX-R cells. 
Histograms summarize quantitative data of means ± S.E.M. of three 
independent experiments (*p<0.05 vs. respective Ctr ; **p<0.01 vs. 
respective Ctr; ****p<0.0001 vs. respective Ctr)  
 
In order to better characterize the metabolic profile of PLX 
resistant cells, the rate of glucose consumption, lactate formation, 
as well as the activity of lactate dehydrogenase (LDH) was 
evaluated. As shown in Figure 18, DMSO treatment did not induce 
changes in glucose consumption (Figure 18 A and B) and in lactate 






release (Figure 18 C and D) in both cell populations. Analogously, 
PLX4032 exposure did not affect the glucose consumption (Figure 
18 B) and the lactate release (Figure 18 D) of PLX-R cells while, 
in DMSO-R cells, it increased significantly both parameters in a 
time-dependent manner, in comparison to respective control 
(Figure 18 A and C). In addition, as shown in the panels C and D 
of Figure 18, untreated DMSO-R cells were more able to release 
lactate (+58%) than PLX-R cells. In regards to the analysis of LDH 
activity, DMSO treatment did not induce changes in both cell 
lines. PLX4032 exposure did not affect LDH activity in PLX-R cells 
(Figure 18 E and F) while, according to the results of lactate 
release, it caused a time-dependent increase in LDH activity in 
DMSO-R cells (Figure 18 E).  
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Figure 18. Analysis of glucose consumption, lactate release and 
LDH activity in DMSO-R and PLX-R cells. PLX exposure did not 
induce metabolic switch in PLX-R cells. Upper panels: Glucose 
consumption was evaluated in untreated and in DMSO or PLX-treated 
(24, 48 and 72 hrs) DMSO-R (A) and PLX-R cells (B). Values are 
expressed as mM glucose/106 cells. Intermediate panels: Extracellular 
lactate concentration was evaluated in untreated and in DMSO or PLX-
treated (24, 48 and 72 hrs) DMSO-R (C) and PLX-R cells (D). Values are 
expressed as mM lactate/106 cells. Lower panels: Lactate dehydrogenase 
(LDH) activity was evaluated in untreated and DMSO or PLX-treated 
(24, 48 and 72 hrs) DMSO-R (E) and PLX-R cells (F). Results are 
reported as U/mg (lactate μmol/min/mg of total protein). Histograms 
summarize quantitative data of means ± S.E.M. of three independent 
experiments (***p<0.001 vs. respective Ctr; ****p< 0.0001 vs. respective 
Ctr). 
  








Melanoma is one of the most lethal forms of skin cancer and its 
incidence continues to increase worldwide [142]. 
A common abnormality found in up to 60% of melanomas and their 
metastases is an activating mutation in the proto-oncogene BRAF, 
which substitutes codon 600 from valine to glutamic acid (V600E) 
and results in a constitutively activated BRAF oncogene and the 
activation of MEK1/2 and, ultimately, of the downstream MAPK 
target, ERK [143]. The activated BRAF→MEK→ERK pathway, 
resulting from the BRAFV600E, has been shown to drive melanoma 
cell proliferation and is implicated in the poor therapeutic 
outcome.  
The relationship between the activated ERK pathway, the 
increased melanoma cell growth and the BRAFV600 mutation has 
led to target this pathway in the treatment of melanoma. In this 
context, PLX4032/Vemurafenib, has been found to induce tumor 
regression in a high percentage of patients with BRAFV600E-
positive metastatic melanoma [74]. However, although treatment 
with this selective inhibitor can control tumor growth, it rarely 
leads to tumor eradication due to an acquired drug resistance [86]. 
The development of the acquired resistance is usually associated 
with the reactivation of the MAPK signalling pathway through 
NRAS or KRAS mutations [91] or alternatively, in the reactivation 
of parallel pathways such as PI3K/AKT [92], or enhanced activity 
of Tirosine-Kinase Receptor (RTK) [93], [99]. In view of these 
limitations, new protocols have been designed in which BRAF-
targeted therapies have been associated with MEK inhibitors 
(MEK-i), such as Trametinib or Cobimetinib [144]. 
However, MEK-i have been unsuccessful both in preclinical 
models and in patients with resistance to BRAF-inhibitors (BRAF-






i) suggesting that other compensatory pathways would be 
involved.  
Thus, these observations highlight urgent need to increase the 
knowledge of the mechanisms underlying therapy resistance in 
melanoma in order to find new therapeutic strategies to overcome 
resistance to BRAF-i. In this context, it is important not limiting 
the research on the study of molecular pathways, but extending 
focus also on the involvement of metabolism in the acquired 
resistance. 
Given that tumors are heterogeneous [131], the pre-clinical model, 
which is used to study in vitro the mechanisms of resistance, needs 
to predict the heterogeneous response of cancer cells in vivo [131]. 
Therefore, the first aim of this PhD thesis was to find an in vitro 
model of a BRAFV600E-mutated human melanoma cell line, in order 
to obtain a more realistic model of drug resistance in comparison 
with the commonly used stabilized cancer cells. 
The model of PLX4032 resistance used in this study is innovative 
since it is performed by treating human melanoma cells, isolated 
from patient’s biopsies, with increasing concentrations of PLX32 
for a long-term period (6 months). In our model, melanoma cells 
adapt to grow in the presence of the drug, while the drug is slowly 
increased. The rate fold increased resistance together with the 
method of selection places this new model in the category of “High-
level laboratory model” as defined by Mc Dermott [131]. This type 
of model is classified as “stably resistant”, and the molecular 
changes associated with the mechanisms of resistance are easily 
identifiable and analysable. In addition, our selection adds the 
pulsed procedure, which provides a recovery time for the cells, 
typical of “Clinical relevant model”. 
This procedure together with the exposure to increasing drug 
concentrations starting from a low dosage (typical of “”High-level 






laboratory model”), tries to mimic the conditions of cancer patients 
during the therapy [131]. 
In the scientific literature, in vitro models, that are employed for 
studying chemoresistance in melanoma, lead to a selection of 
melanoma cells, isolated from human specimens, by using high 
concentrations of PLX administered for a shorter period of 
exposure (5 days) [131], [145] or from stabilized melanoma cell 
lines treated with PLX for different times (2-3 weeks up to 2-3 
months) [99]. 
Therefore, our model can better mimic the in vivo condition and 
the characterization of PLX4032-sensitive and -resistant 
BRAFV600E mutant melanoma cell lines may provide more 
promising information about the molecular mechanisms that 
dictate sensitivity and resistance to PLX4032. 
Among the key factors potentially responsible for the reactivation 
of pro-survival signaling pathways, leading to an acquired 
resistance to BRAF-i therapy, melanoma cell metabolism has been 
demonstrated to play a relevant role [146]. 
In this context, it is widely observed that the metabolic profile of 
cancer is very heterogeneous because metabolic pathways are 
intrinsically driven by oncogenic mutations, tumor suppressor 
gene inactivation and aberrant activation of proliferative 
pathways [147]. Metastatic melanoma are characterized by their 
strict dependence on glucose or glutamine for proliferation [117] 
and in approximately 90% of melanomas the metabolic phenotype 
is associated with low mitochondrial bioenergetic activity [50].  
In this study, it has been demonstrated that chronic PLX exposure 
of human melanoma cells leads to the suppression of glycolysis, 
the maintenance of a functional mitochondrial reticulum and the 
reactivation of OXPHOS as a mechanism of metabolic adaptation 
that limits the efficacy of BRAF inhibitors. On the other hand, 






PLX-sensitive melanoma cells have a glycolytic profile, 
accompanied by a lower ATP synthesis and a loss of mitochondria 
organization. 
This metabolic reprogramming is commonly found in cancer [148] 
and is recently considered as an hallmark of cancer [149] but its 
role in drug resistance needs to be further investigated. 
Moreover, changes in the metabolic profile of cancer cells are 
accompanied by phenotypic changes that may be related to each 
other.  
In fact, in our model, DMSO-resistant cells, differently from the 
resistant counterpart, show an evident glycolytic flux and have a 
better capacity to migrate. 
According to these results, Keren Yizhak et al. by using a 
computational model-based investigation across cancer cell lines, 
showed that the ratio between glycolytic pathway and oxidative 
ATP flux rate is significantly associated with cancer migratory 
behaviour [150]. Moreover, the correlation between glycolytic 
activity and migration was confirmed also by De Bock et al 
showing that endothelial cells silenced for the glycolytic regulator 
PFKB3 have an impaired cell migration capacity. 
However, the metabolic machinery of melanoma cells is not rigid 
and mitochondria are likely to have a key role in the metabolic 
flexibility of melanoma.  
Recently, it has been demonstrated that metastatic melanomas 
with activation of the oncogenic BRAF/MAPK pathway have 
suppressed levels of microphthalmia-associated transcription 
factor (MITF) [151], which is the melanocyte lineage factor and, 
consequently the depletion of its target PGC1α, the transcription 
factor responsible for mitochondrial biogenesis [152] leading to a 
decreased oxidative metabolism. 






In our cellular model, MITF is expressed and equally present in 
PLX-sensitive and PLX-resistant melanoma cells. Moreover, the 
production of reactive oxygen species (ROS) is lightly enhanced in 
PLX-R cells after 72 hrs of PLX exposure. 
Therefore, an efficient mitochondrial activity and the ability to 
maintain low levels of ROS might contribute to sustain PLX 
resistance favoring melanoma cell survival.  
Recently, Piskounova et al. found that melanoma cells, isolated 
from the circulation and from metastatic sites, displayed higher 
levels of ROS than those from the primary tumor, and that the 
metastatic tumors showed a reversible elevation in the production 
of NAPDH, which has been correlated with an increased 
regeneration of glutathione (GSH) [153]. Since GSH is essential to 
guarantee a limited production of ROS and its homeostasis is 
crucial in cancer cell survival [154], further studies are needed to 
better investigate the oxidative metabolism of PLX sensitive and 
PLX resistant cells in order to identify the Achille’s heel of PLX 
resistant melanoma cells. 
Then, the long-term treatment of BRAF-mutated melanoma with 
PLX4032, which reduces the capacity of melanoma cells to form 
colonies and to migrate, induces oxidative phosphorylation that 
might represent an adaptive metabolic program which is able to 
limit the efficacy of the therapy. 
  








In contrast to cytostatic shotgun chemotherapy, new cancer drugs 
are “targeted” and directed towards molecular factors controlling 
cancer expansion processes. To date, the use of these biological 
compounds unfortunately leads as other therapy to the selection 
of small resistant sub-populations of tumor cells after a prolonged 
treatment with the drug. 
However, given the variability of the mechanisms involved, 
overcoming the resistance to BRAF inhibitors remains challenging 
and there is an ongoing effort to identify biomarkers related to the 
molecular and metabolic features of the tumor which may 
determine the efficacy of targeted therapies.  
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